SEC Filing | Jazz Pharmaceuticals plc

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Carr Patricia

(Last)

(First)

(Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/07/2019

3. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
VP, Finance& PAO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	4,600⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Non-Qualified Stock Option (right to buy)	⁽²⁾	02/24/2026	Ordinary Shares	1,980	123.36	D
Non-Qualified Stock Option (right to buy)	⁽³⁾	03/01/2027	Ordinary Shares	5,250	136.18	D
Non-Qualified Stock Option (right to buy)	⁽⁴⁾	02/27/2029	Ordinary Shares	4,250	140.03	D
Non-Qualified Stock Option (right to buy)	⁽⁵⁾	02/29/2028	Ordinary Shares	4,500	140.67	D
Non-Qualified Stock Option (right to buy)	⁽⁶⁾	02/26/2024	Ordinary Shares	4,000	166.62	D
Non-Qualified Stock Option (right to buy)	⁽⁷⁾	02/25/2025	Ordinary Shares	4,500	175.19	D

Explanation of Responses:

1. Consists of (1) 500 restricted stock units of the 2,000 originally granted on February 25, 2016 (1,500 having been released and sold), (2) 1,050 restricted stock units of the 2,100 originally granted on March 2, 2017 (1,050 having been released and sold), (3) 1,350 restricted stock units of the 1,800 originally granted on March 1, 2018 (450 having been released and sold), and (4) 1,700 restricted stock units granted on February 28, 2019, all of which were granted pursuant to the Issuer?s 2011 Equity Issuer Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Each grant of restricted stock units vests in four equal annual installments, and the remaining unvested restricted stock units will vest on various dates between February 25, 2020 and March 5, 2022.

2. These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 25, 2016, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.

3. These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.

4. These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 28, 2019, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.

5. These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 1, 2018, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.

6. These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vested over four years measured from the grant date, February 27, 2014, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. The option is fully vested and exercisable as of the date of this Form.

7. These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vested over four years measured from the grant date, February 26, 2015, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. The option is fully vested and exercisable as of the date of this Form.

	By: /s/Peter A Christou, as attorney in fact For: Patricia Carr	08/12/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby
constitutes and appoints each of VALERIE PIERCE,
PETER A. CHRISTOU, DORIS CHOI, PAZ DIZON and JOLEEN COX
signing individually, the undersigned's true and
lawful attorneys-in fact and agents to:
1)execute for and on behalf of the undersigned (a) Forms 3, 4
and 5 in accordance with Section 16(a) of the Securities
Exchange Act of 1934, as amended (the "Exchange Act") and the
rules thereunder and (b) Forms 144 in accordance with Rule 144
promulgated under the Securities Act of 1933, as amended, as
such Rule may be amended from time to time (or any successor
rule) ("Rule 144");
2)do and perform any and all acts for and on behalf of the
undersigned that may be necessary or desirable to complete and
execute such Forms 3, 4, 5 or 144 (collectively, the "Forms"),
complete and execute any amendment or amendments thereto, and
timely file such Forms or amendments with the U.S. Securities
and Exchange Commission and any stock exchange or similar
authority; and
3)take any other action of any nature whatsoever in
connection with the foregoing which, in the opinion of such
attorney-in-fact, may be of benefit, in the best interest of, or
legally required by, the undersigned, including but not limited
to executing and delivering for and on behalf of the undersigned
any seller's representation letter that may be required to be
submitted to any broker effecting any sale of securities issued
by Jazz Pharmaceuticals plc (the "Company") for the account of
the undersigned, it being understood that the documents executed
by such attorney-in-fact on behalf of the undersigned pursuant
to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may
approve in such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact
full power and authority to do and perform any and every act and
thing whatsoever requisite, necessary, or proper to be done in
the exercise of any of the rights and powers herein granted, as
fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution
or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or
substitutes, shall lawfully do or cause to be done by virtue of
this power of attorney and the rights and powers herein granted.
The undersigned acknowledges that the foregoing attorneys-in-
fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company or any of its
affiliates, assuming, any of the undersigned's responsibilities
to comply with (a) Section 16 of the Exchange Act and (b) all of
the applicable conditions of the Rule 144 safe harbor with
respect to a sale of securities issued by the Company.
	This Power of Attorney shall remain in full force and
effect until the earliest to occur of (a) the undersigned is no
longer required to file any Forms with respect to the
undersigned's holdings of and transactions in securities issued
by the Company, (b) revocation by the undersigned in a signed
writing delivered to the foregoing attorneys-in-fact or (c) as
to any attorney-in-fact individually, until such attorney-in-
fact shall no longer be employed by the Company or an affiliate
of the Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of this 30th day of July 2019.
/s/ Patricia Carr
PATRICIA CARR